Hugel announced on Friday that it successfully showcased the excellence of its botulinum toxin and hyaluronic acid (HA) filler products at the Thai Dermatology Conference.
The company participated in the annual academic conference of the Dermatological Society of Thailand (DST) from Wednesday to Friday at the Centara Grand at CentralWorld in Bangkok, alongside its local partners.
This year marked the 50th edition of DST, Thailand’s largest dermatological conference. The event brought together local medical professionals and aesthetic practitioners to share cutting-edge research findings and the latest treatment trends.
During the conference, Hugel promoted its botulinum toxin product Botulax (marketed as Estox in Thailand) and HA filler TheChaeum (marketed as Revolax internationally). The company also hosted a dedicated academic program to share global clinical experiences and treatment expertise related to Rivolux.
On Tuesday, the day before the event officially began, Hugel organized a Revolax Experts Private Roundtable. French plastic surgeon Dr. Lyor Hanan was the keynote speaker, offering in-depth insights into practical applications and clinical considerations.
The following day, during a symposium, Thai dermatologist Dr. Pitchaya Maneeprasopchoke presented clinical data and practical application techniques for Revolax specifically tailored to Thai patients, which garnered significant interest from attendees.
A Hugel spokesperson commented that Thailand represents the largest market in Southeast Asia and a key focus for global aesthetic companies. The participation in this prominent conference, attended by the majority of local dermatologists, allowed them to strengthen our academic foundation and engage meaningfully with medical professionals. It was an incredibly valuable experience.